MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Dexamethasone Sodium Phosphate 4.37 mg/mL Injection (Solution, 100 mL)	FIN	F 002 028

NOTE: Dexamethasone Sodium Phosphate 4.37 mg/mL is equivalent to Dexamethasone Phosphate 4 mg/mL.

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Dexamethasone Sodium Phosphate, USP	0.437	g				
Benzyl Alcohol, NF	1.00	g				
Sodium Sulfite	0.10	g				
Sodium Citrate, USP	1.906	g				
Sterile water for injection, USP	80.0	mL				
Sterile water for injection, USP	100.0	mL				
Citric Acid 10% Solution	As required					
Sodium Hydroxide 10% Solution	As required					

Suggested Formula	Dexamethasone Sodium Phosphate 4.37 mg/mL Injection (Solution, 100 mL)	FIN	F 002 028

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Light sensitive *(protect from light whenever possible):* *Benzyl Alcohol, Sodium Sulfite Dexamethasone Sodium Phosphate*

Hygroscopic *(protect from moisture whenever possible):* *Dexamethasone Sodium Phosphate*

Suggested Preparatory Guidelines

☐ Non-Sterile Preparation ■ Sterile Preparation

Processing Error / Testing Considerations: To account for processing error, pH, sterility and endotoxin testing considerations during preparation, it is suggested to measure an additional **5 to 9%** of the required quantities of ingredients.

Special Instruction: This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within *USP 797*. Only trained and qualified personnel must prepare this formula.

All heat stable, reusable materials and equipment must be sterilized and depyrogenated by dry heat sterilization at 250°C for 2 hours prior to use.

Every batch of final product compounded using this procedure must be sterility and endotoxin tested before being dispensed.

Protective apparel, such as a sterile gown, sterile gloves, shoe covers, head cap, eyewear and face-masks should always be worn. In addition, proper personnel cleansing must be done before entering the buffer or clean area.

Filter integrity must be validated by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.

Suggested Formula	Dexamethasone Sodium Phosphate 4.37 mg/mL Injection (Solution, 100 mL)	FIN	F 002 028

SUGGESTED PREPARATION (for 100 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*): ____	Processing Error	Qty. to measure
Dexamethasone Sodium Phosphate, USP §	0.437	g			
Benzyl Alcohol, NF §	1.00	g			
Sodium Sulfite §	0.10	g			
Sodium Citrate, USP §	1.906	g			
Sterile water for injection, USP §	80.0	mL			
Sterile water for injection, USP §	100.0	mL			
Citric Acid 10% Solution §	As required				
Sodium Hydroxide 10% Solution §	As required				

* Takes into account increased batch size conversions and density conversions, if required.
§ Weigh / measure just prior to use.

Preparatory Instruction

IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique

1. **Equipment sterilization:**

   Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and equipment, then return to ambient temperature.

2. **Powder-liquid preparation:**

   A. Combine and triturate the following ingredients together to form a fine, homogeneous powder blend:

   - Dexamethasone Sodium Phosphate
   - Sodium Sulfite
   - Sodium Citrate

   B. Levigate the homogeneous powder blend (Step 2A) with the following ingredient:

   - Benzyl Alcohol

   End result: Homogeneous paste-like dispersion

3. **Powder-liquid to medium incorporation:**

   A. Incrementally add the homogeneous paste-like dispersion (Step 2B) to the following ingredient:

   - Sterile water for injection (80.0 mL plus processing error adjustments)

   Specification: Continuously mix until all solid particles have completely dissolved.

   End result: Homogeneous liquid-like solution

Suggested Formula	Dexamethasone Sodium Phosphate 4.37 mg/mL Injection (Solution, 100 mL)	FIN	F 002 028

4. **pH testing:**

A. Draw an appropriate amount of the mixture (Step 3A).

B. Test the pH of the sample. It should lie between 7.0 and 8.5.

C. If the pH < 7.0, carefully add in a dropwise manner the Sodium Hydroxide 10% solution to the mixture:

1. Draw and transfer 1 or 2 drops of the Sodium Hydroxide 10% solution to the mixture.
2. Stir for at least 5 minutes to evenly disperse the Sodium Hydroxide 10% solution.
3. Re-test the pH.
4. Continue to add the Sodium Hydroxide 10% solution until the pH of 7.0 to 8.5 is obtained.

IMPORTANT: Do not allow the pH to rise above 8.5.

D. If the pH > 8.5, carefully add in a dropwise manner the Citric Acid 10% solution to the mixture:

1. Draw and transfer 1 or 2 drops of the Citric Acid 10% solution to the mixture.
2. Stir for at least 5 minutes to evenly disperse the Citric Acid 10% solution.
3. Re-test the pH.
4. Continue to add the Citric Acid 10% solution until the pH of 7.0 to 8.5 is obtained.

IMPORTANT: Do not allow the pH to fall below 7.0.

5. **Filling to volume:**

A. Add additional Sterile water for injection to the above mixture to fill to the required batch size (100.0 mL *plus* processing error adjustments).

Specification: Continuously mix

End result: Homogeneous liquid-like solution

6. **Filtering and transferring:**

Aseptically filter the solution through a 0.22-µm sterile filter into the recommended dispensing container (see Packaging requirements). Transfer the remainder into a separate dispensing container. This is to be used as the Test sample for sterility and endotoxin testing.

7. **Filter integrity test:**

Validate filter integrity by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.

8. **Sterility testing:**

Validate the Test sample for sterility and endotoxins, in accordance to current USP 797 regulatory guidelines.

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Dexamethasone Sodium Phosphate 4.37 mg/mL Injection (Solution, 100 mL)	FIN	F 002 028

SUGGESTED PRESENTATION

Estimated Beyond-Use Date		14 days, refrigerated. BUD based on a successful sterility and endotoxin test result.	Packaging Requirements		Sterile, light-resistant 1 mL unit-dose vials.
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.		6	Keep refrigerated. Do not freeze.
	2	Keep out of reach of children.		7	Equilibrate to room temperature before use.
	3	Discard container after use.		8	**Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.**
	4	Discard in the presence of particulate matter.		9	Do not use if discolored.
	5	Protect from light.			
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.				
Patient Instructions	Contact your pharmacist in the event of adverse reactions.				

Suggested Formula	Dexamethasone Sodium Phosphate 4.37 mg/mL Injection (Solution, 100 mL)	FIN	F 002 028

REFERENCES

1. USP <797> Pharmaceutical Compounding – Sterile Preparations. US Pharmacopeial Convention, Inc. *United States Pharmacopeia XXVIII / National Formulary 23.* Rockville, MD. 2004: 2461.
2. Parenteral Preparations. In: Allen, LV, Jr. *The Art, Science and Technology of Pharmaceutical Compounding.* American Pharmaceutical Association; 1998: 251.
3. Dexamethasone Sodium Phosphate Injection, USP. In: Canadian Pharmacists Association. *Compendium of Pharmacists and Specialties, 2005.* 619.
4. Benzyl Alcohol. In: Rowe RC. *Handbook of Pharmaceutical Excipients, 4th Edition.* American Pharmaceutical Association; 2003: 53.
5. Sodium Citrate Dihydrate. In: Rowe RC. *Handbook of Pharmaceutical Excipients, 4th Edition*. American Pharmaceutical Association; 2003: 560.
6. Dexamethasone Sodium Phosphate. In: Sweetman SC, ed. *Martindale: The Complete Drug Reference, 34th Edition.* London, England: The Pharmaceutical Press; 2005: 1097.
7. Dexamethasone Sodium Phosphate (Monograph). In: O'Neil MJ. *The Merck Index 13th Edition*. Whitehouse Station, NJ: Merck & Co, Inc.; 2001: 518.
8. Chapter 18: Tonicity, Osmoticity, Osmolaltiy and Osmolarity. In: Gennaro AR. *Remington: The Science and Practice of Pharmacy, 20th Edition.* Baltimore, MD: Lippincott Williams & Wilkins; 2000: 246~262.
9. Dexamethasone Sodium Phosphate. In: Trissel LA. *Trissel's Stability of Compounded Formulations, 2nd Edition.* American Pharmaceutical Association; 2000: 119.
10. Dexamethasone Sodium Phosphate (Monograph). US Pharmacopeial Convention, Inc. *United States Pharmacopeia XXV / National Formulary 20.* Rockville, MD. 2001: 524.
11. Dexamethasone Sodium Phosphate Injection. US Pharmacopeial Convention, Inc. *United States Pharmacopeia XXV / National Formulary 20.* Rockville, MD. 2001: 527.
12. Chapter 8: Buffered and Isotonic Solutions. In: Martin, A. *Physical Pharmacy, Fourth Edition.* Philadelphia, PA: Lipponcott Williams & Wilkins; 1993: 169~189.